Catalyst
Slingshot members are tracking this event:
Phase 2 dose ranging trial preliminary data of Iclusig (ponatinib) for thrid line chronic-phase CML (CP-CML) due end of 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ARIA | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 15, 2016
Occurred Source:
http://investor.ariad.com/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=2202045
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2, Iclusig, Ponatinib, Chronic-phase Cml, Optic Trial, Cytogenetic Response
